Clinical trial NCT05658835: Interest of Molecular Analysis of Cerebral Thrombi in Determining the Prognosis and Etiology of Cerebral Infarction
Official title: Interest of Molecular Analysis of Cerebral Thrombi in Determining the Prognosis and Etiology of Cerebral Infarction
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Ischemic Stroke
Keywords: ischemic stroke
thrombi
metabolites
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2022-12-21
Enrollment: 311
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients suffering from ischemic stroke

Brief summary: The MATISSE (Molecular Analysis of Thrombus for Ischemic Stroke prognosis and Etiology) project evaluates the hypothesis that the molecular composition of cerebral thrombus in metabolites, lipids, and proteins conditions the clinical prognosis at 3 months of the infarction and informs on its etiological subtype


Eligibility criteria: Inclusion Criteria:

* Male or female 18 years of age or older;
* Patient with a cerebral infarction documented by brain imaging who received endovascular treatment by mechanical thrombectomy;
* Patient for whom it was possible to collect cerebral thrombus for LC-MS analysis during mechanical thrombectomy:
* Patient who was informed of the study and formulated a non-opposition to participation. If not, patient for whom a relative was informed and formulated a non-opposition.

Exclusion Criteria:

* Patient with a cerebral infarction documented by cerebral imaging, having benefited from an endovascular treatment with mechanical thrombectomy that did not allow the extraction of a cerebral thrombus.
* Protected persons (articles L1121-5, L1121-6 and L121-8 of the Public Health Code): pregnant or breast-feeding women, persons deprived of liberty, under guardianship or curatorship

Primary outcomes:
measure: Determination and validation of molecular signatures, obtained by LC-MS analysis of cerebral thrombi, predictive of the excellent clinical prognosis
timeFrame: 3 months after the cerebral infarction
Secondary outcomes:
measure: Determination and validation of molecular signatures, obtained by LC-MS analysis
timeFrame: 7 days after the cerebral infarction
measure: Determination and validation of molecular signatures, obtained by LC-MS analysis
timeFrame: 3 months after the cerebral infarction
measure: Severe intracranial hemorrhage
timeFrame: 3 months after the cerebral infarction
measure: Recovery of autonomy in walking
timeFrame: 3 months after the cerebral infarction
measure: Recovery of autonomy in walking
timeFrame: 7 days after the cerebral infarction
measure: Early Neurological Deterioration
timeFrame: 24 hours after recanalization treatment
measure: Use of thrombolytic therapy in the acute phase
timeFrame: Before thrombectomy
measure: Determination of molecular signatures predictive on successful recanalization after mechanical thrombectomy
timeFrame: Right after the thrombectomy
measure: Positive infarct growth after successful recanalization
timeFrame: Between 24 and 48h after the thrombectomy
measure: Death
timeFrame: 3 months after cerebral infarction
measure: Patient exposure to peak outdoor air pollution
timeFrame: 96 hours before cerebral infarction
Other outcomes:
Locations:
city: Fort-de-France
country: France
facility: CHU Martinique
city: Marseille
country: France
facility: Stroke Center
city: Pointe-à-Pitre
country: France
facility: CHU Guadeloupe
city: Saint-Pierre
country: France
facility: CHU La Réunion
Study officials:
affiliation: AP-HM
name: François Crémieux
role: STUDY_DIRECTOR
References: